Rating Change
HC Wainwright & Co. reiterated its Buy rating on Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) on November 06, 2026.
reiterateNASDAQ:XERS
HC Wainwright & Co. Reiterates Buy Rating on Xeris Biopharma Holdings, Inc. (XERS)
HC Wainwright & Co. reiterated its Buy rating on Xeris Biopharma Holdings, Inc.
At publication ·
What changed
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) · reiterate
- Firm
- HC Wainwright & Co.
- Rating
- Buy to Buy
- Price at event
- $14.91
- Market capitalization
- $1.2B
At a glance
Key takeaways
- HC Wainwright & Co. reiterated a Buy rating on Xeris Biopharma (XERS) on November 6, 2026, with the stock trading at $14.90 and a market cap of $1.2 billion.
Market Context
Xeris Biopharma Holdings, Inc. operates in the Healthcare sector. The stock currently trades at $14.90 with a market capitalization of $1.2B.
Analyst coverage from HC Wainwright & Co. provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Xeris Biopharma Holdings, Inc.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Xeris Biopharma Holdings, Inc.
Among the 10 most recent ratings: 9 Buy, 1 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Nov 06, 2026 | Piper Sandler | Neutral | N/A |
| Nov 06, 2026 | HC Wainwright & Co. | Buy | N/A |
| Oct 06, 2026 | Barclays | Overweight | N/A |
| Sep 10, 2026 | Leerink Partners | Outperform | N/A |
| Aug 20, 2026 | Barclays | Overweight | N/A |
Related Tools: Analyst Ratings Dashboard | View XERS Stock Page
Frequently Asked Questions
What does the Buy rating mean for XERS?
A rating of Buy from HC Wainwright & Co. reflects the analyst's outlook on Xeris Biopharma Holdings, Inc. (NASDAQ:XERS). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the XERS forecast page.